Adult asthma is treated using two types of pharmacotherapy: rescue therapy to treat acute symptoms via bronchodilation (e.g., a SABA) and...
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA) and...
Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatment of...
The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’...
Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling...
Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling...
MARKET OUTLOOK The dynamics within the LABA/ICS FDC, LAMA, and biological drug classes will continue to shape the U.S. asthma market. The...
Dupixent (Sanofi / Regeneron), a first-in-class biologic that inhibits IL-4 / IL-13 signaling, was approved for the treatmen...
Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling...
Mylan’s salmeterol / fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK’s Advair, one of the top-selling...
MARKET OUTLOOK Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma...
Pediatric asthma pharmacotherapy has two main goals: to address underlying airway inflammation and to promote bronchodilation. Physicians use two...
Pharmacotherapy for adult asthma has two main goals: address underlying airway inflammation and promo...
Dupixent (Sanofi/Regeneron), a first-in-class biologic that inhibits IL-4/IL-13 signaling, was approved for the treatment of eosi...
The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair/Seretide, AstraZeneca’s...
Market Outlook The asthma market in the EU5 is highly competitive. A large number of approved agents are available inc...
MARKET OUTLOOK Despite the availability of multiple anti-inflammatory agents and bronchodilators, considerable unmet need remains for patients with...
DRG Epidemiology's coverage of asthma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report...
Get content updates to your inbox
Subscribe